The Product Safety & Liability Reporter™ provides updates on significant developments and issues in product safety and liability litigation and regulation, plus analysis from top litigators. Get...
Aug. 31 — Bayer Healthcare must face some claims by an Idaho couple alleging the wife became pregnant about a year after receiving an Essure permanent contraceptive device ( Richardson v. Bayer Healthcare Pharm., Inc. , 2016 BL 282974, D. Idaho, No. 15-00443, 8/30/16 ).
Most of Susan and Brian Richardson’s claims were barred by federal medical device law, the U.S. District Court for the District of Idaho said Aug. 30.
But the court allowed claims that Bayer Healthcare Pharmaceuticals Inc., whose parent company is Bayer AG, and related companies failed to report certain adverse events to the Food and Drug Administration.
The Essure device was conditionally approved under the FDA’s premarket approval process. Therefore only independent state-law claims based on the violation of a federal requirement could survive.
Idaho law provides the basis for such a claim, the court said.
The court followed the reasoning of Stengel v. Medtronic, Inc., 704 F.3d 1224 (9th Cir. 2013). There, the U.S. Court of Appeals for the Ninth Circuit allowed claims that a device maker violated an independent duty under Arizona law when it failed to adhere to federal device reporting regulations.
Idaho law similarly provides an independent remedy: A medical device maker’s duty to warn should be construed to include reports to the FDA, the court said.
Although the Richardsons failed to allege they wouldn’t have used Essure had the information been disclosed to the FDA, a jury must determine how disclosure would have affected the adequacy of the warning to the plaintiffs, it said.
Aherin Rice & Anegon represented the plaintiffs.
Elam & Burke, P.A. represented Bayer.
To contact the reporter on this story: Julie A. Steinberg in Washington at email@example.com
The opinion is available at http://www.bloomberglaw.com/public/document/Richardson_et_al_v_Bayer_HealthCare_Pharmaceuticals_Inc_et_al_Doc.
Copyright © 2016 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)